Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Partners with AstraZeneca on Prostate Cancer Targets

NEW YORK, Nov. 1 (GenomeWeb News) - Caprion and AstraZeneca will collaborate to develop therapies for prostate cancer, Caprion Pharmaceuticals said today.

 

Under the agreement, AstraZeneca will evaluate prostate cancer drug targets discovered by Caprion and obtain exclusive, worldwide rights to develop and commercialize therapeutic applications for selected targets. Caprion will retain rights to other targets.

 

AstraZeneca will pay Caprion an unspecified amount for up-front payment and license fees. The company will make additional payments contingent on its meeting certain development and commercialization milestones.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.